JAMA Psychiatry

Utility of Wrist-Wearable Data for Assessing Pain, Sleep, and Anxiety Outcomes after Traumatic Stress Exposure.  80:220-229. 2023

Contrasting Case-Control and Normative Reference Approaches to Capture Clinically Relevant Structural Brain Abnormalities in Patients with First-Episode Psychosis Who Are Antipsychotic Naive.  79:1133-1138. 2022

Erratum: Prevention of recurrence after recovery from a major depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: phase 2 of a 2-phase randomized clinical trial (JAMA Psychiatry (2019) DOI: 10.1001/jamapsychiatry.2019.3900).  77:328. 2020

Prevention of Recurrence after Recovery from a Major Depressive Episode with Antidepressant Medication Alone or in Combination with Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial.  77:237-245. 2020

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial.  76:893-903. 2019

Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States.  75. 2018

Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial.  75:139-148. 2018

Paving the way for targeted drug development in schizophrenia.  75:19-20. 2018

Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia.  74:37-46. 2017

Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial.  73:928-937. 2016

Notice of Retraction and Replacement. Hollon et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2014;71(10):1157-1164.  73:639-640. 2016

Association of DNA methylation differences with schizophrenia in an epigenome-wide association study.  73:506-514. 2016

The course of illness after initial diagnosis of major depression.  73:321-322. 2016

Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia a randomized clinical trial.  72:822-829. 2015

Venlafaxine extended-release for depression following spinal cord injury a randomized clinical trial.  72:247-258. 2015

Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder a randomized clinical trial.  71:1157-1164. 2014

Multicenter pilot treatment trial for psychogenic nonepileptic seizures: A randomized clinical trial.  71:997-1005. 2014

Identification of pathways for bipolar disorder: A meta-analysis.  71:657-664. 2014

In reply.  71:339-340. 2014

Risky decision making, prefrontal cortex, and mesocorticolimbic functional connectivity in methamphetamine dependence.  71:812-820. 2014

Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.  70:1267-1275. 2013

Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.  70:1294-1302. 2013

From perception to functional outcome in schizophrenia: Modeling the role of ability and motivation.  69:1216-1224. 2012

Functional neuroanatomy of visual masking deficits in schizophrenia.  66:1295-1303. 2009

Personality change during depression treatment: A placebo-controlled trial.  66:1322-1330. 2009

Depressive symptom dimensions and cardiovascular prognosis among women with suspected myocardial ischemia: A report from the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.  66:499-507. 2009

Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression.  66:324-330. 2009

Selecting among second-step antidepressant medication monotherapies: Predictive value of clinical, demographic, or first-step treatment features.  65:870-881. 2008

Depression symptom severity and reported treatment history in the prediction of cardiac risk in women with suspected myocardial ischemia: The NHLBI-Sponsored WISE Study.  63:874-880. 2006

Differential and brain region-specific regulation of Rap-1 and Epac in depressed suicide victims.  63:639-648. 2006

Cognitive therapy vs medications in the treatment of moderate to severe depression.  62:409-416. 2005

Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.  62:417-422. 2005

Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: A postmortem brain study.  61:685-693. 2004

Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects.  60:804-815. 2003

Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects.  60:273-282. 2003

Serum thyrotropin concentrations and bioactivity during sleep deprivation in depression.  58:77-83. 2001

Decisional capacity for informed consent in schizophrenia research.  57:533-538. 2000

Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study.  57:1061-1069. 2000

Smooth pursuit eye movements to extraretinal motion signals: Deficits in relatives of patients with schizophrenia.  55:830-836. 1998

Specific measures account for most of the variance in qualitative ratings of smooth pursuit eye movements in schizophrenia..  55:184-186. 1998

Naltrexone and alcohol dependence: Role of subject compliance.  54:737-742. 1997

Psychiatric Morbidity in Research Volunteers.  47:980. 1990